drugset / Trial / NCT06235086
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.
Timeline
- Start
- 2024-04-08
- Primary completion
- 2026-02-03
- Completion
- 2026-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | — | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 7.5 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |